Pegfilgrastim biologics discount contracts (open house) 2026-05
Original notice title
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-05 - Pegfilgrastim
Opportunity Score
Why this score?
Opportunity
0 / 100
Complexity
0 / 100
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Techniker Krankenkasse
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Apr 29, 2028
AI tender analysis
Tenderwize prepares an AI analysis of this tender based on the TED notice and procurement documents: scope of work, key requirements, eligibility criteria, risks and questions for the buyer. The analysis is generated when the tender is opened.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open-House-Biologika-Rabattverträge 2026-05 - Pegfilgrastim
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Pegfilgrastim im Rahmen eines Open-House-Verfahrens.
Location
Duration
Category
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Pegfilgrastim im Rahmen eines Open-House-Verfahrens.
Procurement Details
- Publication date
- 17 Nov 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 802501-2026
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-09 - Etanercept
Germany – Pharmaceutical products – Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny L04AC21 s účinnou látkou BIMEKIZUMAB
Norway – Medical equipments, pharmaceuticals and personal care products – Framework agreement for medicines and multi-dose.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 15 Ranibizumab
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-24 - Aflibercept (ATC: S01LA05; Wirkstärke: 40 mg/ml)
Opportunity Score
Why this score?
Opportunity
0 / 100
Complexity
0 / 100
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications